Background Her-2/neu gene overexpression has been found in several malignancies, and is associated with poor prognosis; while its role in the tumorigenesis and progression of prostate cancer （PCa） is still controver...Background Her-2/neu gene overexpression has been found in several malignancies, and is associated with poor prognosis; while its role in the tumorigenesis and progression of prostate cancer （PCa） is still controversial. This study aimed to evaluate the prognostic value of Her-2/neu protein expression and clinicopathologic factors in antiandrogen-treated Chinese men with PCa for disease progression and PCa-specific death. Methods Her-2/neu protein expression was determined using immunohistochemistry （IHC） in specimens collected from 124 prostate biopsies and transurethral resection of prostate （TURP） from seven prostate cancer patients. Results Her-2/neu protein expression was 0, 1＋, 2＋, and 3＋ in 40 （30.5%）, 8 （6.1%）, 67 （51.1%）, and 16 （12.2%） cases respectively. Her-2/neu protein expression showed significant correlation as judged by Gleason score （P=0.049）, clinical tumor-node-metastases （cTNM） stage （P=0.018） and disease progression （P=0.001）, but did not correlate with prostate-specific antigen （PSA） （P=0.126） or PCa-specific death （P=0.585）. PSA （P=0.001）, Gleason score （P=0.017）, cTNM （P=-0.000） and Her-2/neu protein expression （P=0.001） had prognostic value for evaluating the progression of PCa in univariate analysis. In Kaplan-Meier plots, both Gleason score （P=0.035） and cTNM （P=0.013） correlated with PCa-specific death. In multivariate analysis, only cTNM was significant for both disease progression （P=0.001） and PCa-specific death （P=0.031）. Conclusions Her-2/neu protein expression is significantly correlated with Gleason score, cTNM and disease progression, although it is not an independent predictor of disease progression and PCa-specific death, cTNM staging serves as an independent prognostic factor for disease progression and PCa-specific death.展开更多
文摘Background Her-2/neu gene overexpression has been found in several malignancies, and is associated with poor prognosis; while its role in the tumorigenesis and progression of prostate cancer （PCa） is still controversial. This study aimed to evaluate the prognostic value of Her-2/neu protein expression and clinicopathologic factors in antiandrogen-treated Chinese men with PCa for disease progression and PCa-specific death. Methods Her-2/neu protein expression was determined using immunohistochemistry （IHC） in specimens collected from 124 prostate biopsies and transurethral resection of prostate （TURP） from seven prostate cancer patients. Results Her-2/neu protein expression was 0, 1＋, 2＋, and 3＋ in 40 （30.5%）, 8 （6.1%）, 67 （51.1%）, and 16 （12.2%） cases respectively. Her-2/neu protein expression showed significant correlation as judged by Gleason score （P=0.049）, clinical tumor-node-metastases （cTNM） stage （P=0.018） and disease progression （P=0.001）, but did not correlate with prostate-specific antigen （PSA） （P=0.126） or PCa-specific death （P=0.585）. PSA （P=0.001）, Gleason score （P=0.017）, cTNM （P=-0.000） and Her-2/neu protein expression （P=0.001） had prognostic value for evaluating the progression of PCa in univariate analysis. In Kaplan-Meier plots, both Gleason score （P=0.035） and cTNM （P=0.013） correlated with PCa-specific death. In multivariate analysis, only cTNM was significant for both disease progression （P=0.001） and PCa-specific death （P=0.031）. Conclusions Her-2/neu protein expression is significantly correlated with Gleason score, cTNM and disease progression, although it is not an independent predictor of disease progression and PCa-specific death, cTNM staging serves as an independent prognostic factor for disease progression and PCa-specific death.
